Biotechnology firm Pharming booked a lost of €15.1m in the first six months of this year, compared with €12.1m in the year earlier period.
The company’s operational costs rose over €2m, due to an increase in research costs connected to the registration of its drug Rhucin.
Pharming plans to submit a new registration request for the drug to the European Union in September. Rhucin is used to treat allergic swelling reactions known as angioedema.
The company said its finances would remain a top priority in the second half of the year and was in talks about raising more capital.
Thank you for donating to DutchNews.nl.
We could not provide the Dutch News service, and keep it free of charge, without the generous support of our readers. Your donations allow us to report on issues you tell us matter, and provide you with a summary of the most important Dutch news each day.Make a donation